Brisbane based battery materials and technology company Novonix announced on Tuesday that it had raised $41.2 million in what it described as a “heavily oversubscribed” share purchase plan (SPP).

Summary,Definition of an Oversubscribed Issue,: An oversubscribed issue occurs when demand for a new offering, such as stocks or bonds, exceeds the number of available shares or bonds. Underwriters ...

Sirius Real Estate, the leading owner and operator of branded business and industrial parks providing conventional space and flexible workspace in Germany and the U.K., has raised €350 million ...

Sygnum raises USD 58 million in oversubscribed growth round, boosting market expansion, product development, and regulatory compliance in digital assets. Sygnum, a global digital asset banking ...

Laxmi Dental's IPO was oversubscribed by 113.97 times on its closing day, with strong demand from all investor categories. The company raised over Rs 314 crore from anchor investors and will use the ...

The price band for the issue is fixed at ₹407-₹428 per share. Choice Equity Broking has recommended subscribing to the IPO for long-term investment, citing the company’s strong market ...

Management notes that this means that that SPP was heavily oversubscribed well in excess of the $5 million target that was initially announced by the company. And while not all valid applications ...

PETALING JAYA: Oriental Kopi Holdings Bhd’s initial public offering (IPO) was oversubscribed by 59.96 times ahead of its upcoming listing on the ACE Market of Bursa Malaysia, slated for Jan 23.

KUALA LUMPUR, Jan 14 (Bernama) -- Food and beverage (F&B) chain operator Oriental Kopi Holdings Bhd’s initial public offering (IPO) has been oversubscribed by approximately 60 times. In a statement ...

KUALA LUMPUR: Oriental Kopi Holdings Bhd’s initial public offering (IPO) was oversubscribed by 59.96 times ahead of its upcoming listing on the ACE Market of Bursa Malaysia, scheduled for Jan 23 ...

SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today ...